Rep. Thomas H. Kean, Jr. Unloads Shares of Johnson & Johnson (NYSE:JNJ)

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on September 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on August 27th. The trade occurred in the Representative’s “STATE STREET BANK & TRUST CO.” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 8/27/2026.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 8/27/2026.
• Purchased $1,001 – $15,000 in shares of MasTec (NYSE:MTZ) on 8/21/2026.
• Sold $1,001 – $15,000 in shares of Stryker (NYSE:SYK) on 7/22/2026.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 7/22/2026.
• Purchased $1,001 – $15,000 in shares of Toast (NYSE:TOST) on 7/8/2026.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 7/8/2026.
• Purchased $1,001 – $15,000 in shares of ESAB (NYSE:ESAB) on 7/7/2026.
• Purchased $1,001 – $15,000 in shares of EQT (NYSE:EQT) on 7/7/2026.
• Sold $1,001 – $15,000 in shares of Analog Devices (NASDAQ:ADI) on 6/30/2026.

Johnson & Johnson Trading Up 0.5%

Shares of JNJ opened at $266.81 on Tuesday. Johnson & Johnson has a 1-year low of $173.33 and a 1-year high of $281.07. The business’s 50-day moving average price is $263.18 and its 200 day moving average price is $246.08. The stock has a market capitalization of $642.99 billion, a P/E ratio of 30.92, a P/E/G ratio of 2.54 and a beta of 0.24. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. During the same quarter in the previous year, the business earned $2.77 earnings per share. The firm’s revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Analysts expect that Johnson & Johnson will post 11.61 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were given a $1.34 dividend. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is 62.11%.

Institutional Investors Weigh In On Johnson & Johnson

Hedge funds and other institutional investors have recently made changes to their positions in the company. California State Teachers Retirement System raised its holdings in shares of Johnson & Johnson by 25,103.8% in the second quarter. California State Teachers Retirement System now owns 943,488,645 shares of the company’s stock valued at $239,617,811,000 after acquiring an additional 939,745,213 shares in the last quarter. Auto Owners Insurance Co grew its holdings in Johnson & Johnson by 22,225.6% during the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after acquiring an additional 69,108,368 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Johnson & Johnson by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company’s stock valued at $11,967,947,000 after purchasing an additional 1,738,292 shares in the last quarter. Norges Bank purchased a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $6,924,523,000. Finally, Wellington Management Group LLP boosted its stake in shares of Johnson & Johnson by 12.5% during the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock valued at $5,736,851,000 after purchasing an additional 2,513,321 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: J&J is reportedly in discussions with Apollo Global Management to sell its DePuy Synthes orthopedics business for approximately $20 billion. A transaction could unlock significant value, provide capital for debt reduction, buybacks or acquisitions, and sharpen the company’s focus on higher-growth businesses. However, DePuy Synthes generated $9.3 billion in sales last year, so investors will weigh proceeds against the loss of ongoing revenue. J&J in talks to sell DePuy Synthes to Apollo for $20 billion
• Positive Sentiment: Phase 3 PAPILLON results for RYBREVANT plus chemotherapy showed median overall survival of 34.3 months in patients with EGFR exon 20 insertion-positive non-small cell lung cancer. The durable benefit strengthens the commercial outlook for a key oncology product and supports J&J’s strategy of offsetting pressure from older medicines. RYBREVANT PAPILLON study results
• Positive Sentiment: Management is targeting double-digit growth despite anticipated biosimilar competition for STELARA, suggesting confidence in new product launches, oncology momentum and broader pharmaceutical diversification. Johnson & Johnson targets double-digit growth
• Neutral Sentiment: At the Morgan Stanley healthcare conference, J&J presented its business outlook and strategy; the available report provides no specific new guidance likely to materially change earnings expectations. Morgan Stanley healthcare conference transcript
• Negative Sentiment: Contineum Therapeutics said the mid-stage trial of JNJ-5120, or PIPE-307, failed to meet its primary objective in major depressive disorder. The failure removes or delays a potential pipeline opportunity, though the financial impact may be limited because the program is partnered. Contineum and J&J depression drug trial
• Negative Sentiment: J&J’s requirement that providers submit claims data to receive 340B discounts could generate pushback from hospitals and safety-net providers, increasing reputational, legal or policy risk around the company’s pricing practices. J&J 340B reporting requirement

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This represents a 56.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Jennifer Taubert sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 87,569 shares of company stock valued at $23,064,544. 0.16% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of research analyst reports. Wall Street Zen downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Weiss Ratings upgraded Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 24th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $282.00 target price on shares of Johnson & Johnson in a research note on Thursday, July 16th. Argus set a $300.00 price target on shares of Johnson & Johnson in a research report on Wednesday, July 29th. Finally, Citigroup boosted their price objective on shares of Johnson & Johnson from $285.00 to $298.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $274.13.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.